Third Harmonic Bio Inc (THRD) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Third Harmonic Bio Inc (THRD), detailing its current stock overview, market capitalization, and various financial assessment dimensions. It highlights that relevant data for EPS and revenue forecasts has not yet been disclosed by the company. The page also outlines links to market data, news, analysis tools, and educational resources provided by TradingKey.
Third Harmonic Bio Inc (THRD) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Third Harmonic Bio Inc (THRD) focusing on its dividend and stock split history. It states that the company has distributed $0.00 in dividends over the past five years and reports no historical data for either dividends or stock splits. The article also includes current stock information such as its market capitalization and recent trading price.
Third Harmonic Bio Inc (THRD) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Third Harmonic Bio Inc (THRD), detailing its support, resistance, indicators, and moving averages. It includes a technical summary based on indicators like MACD, RSI, and KDJ, with a current signal of "Buy" based on moving averages. The analysis also covers definitions of technical ratings and moving averages, and answers FAQs regarding THRD's technical status.
Third Harmonic Bio Inc (THRD) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis for Third Harmonic Bio Inc (THRD), focusing on its P/E, P/B, and Fair Value. It reports that relevant data for these metrics have not been disclosed by the company yet. The page displays current stock information and links to other financial analysis tools.
Third Harmonic Bio Inc (THRD) Institutional Confidence
This article from TradingKey provides an overview of Third Harmonic Bio Inc (THRD), focusing on its institutional confidence score. It details the company's market capitalization, current stock price, and shareholder activity, noting Novartis AG's holdings. The article is part of TradingKey's broader analysis tools, including financial health, valuation, earnings forecast, price momentum, and risk assessment.
AnaptysBio Appoints New CFO and Board Director
AnaptysBio Inc. has appointed Christopher M. Murphy as its new Chief Financial Officer, formalizing his role with performance-based compensation and a substantial equity grant. The company also expanded its board of directors by appointing Owen Hughes as a Class I director, granting him restricted stock units. These appointments aim to strengthen executive leadership and board oversight, aligning incentives for a potentially transformative period for the company.
Third Harmonic Bio Inc THRD
This page provides an overview of Third Harmonic Bio Inc (THRD) stock, showing its current price of $5.380, market cap of $241.86M, and performance. It also offers sections for financials, discussions, and analysis related to the company. The platform, TradingKey, provides various market data, news, analysis tools, and educational resources.
Natalie Holles named CEO and President of Aura; Dr. Elisabet de los Pinos to Depart
Aura Biosciences has appointed Natalie Holles as its new Chief Executive Officer and President, effective April 30, 2026. She succeeds founder Dr. Elisabet de los Pinos, who departed but will continue to provide consulting services until October 30, 2026. Holles brings extensive experience from previous CEO roles in the biotechnology sector.
Third Harmonic Bio gets shareholder nod to wind down operations
Third Harmonic Bio has received shareholder approval to wind down its operations, a decision made after the company discontinued the development of its lead drug, THB001. The company's board believes that liquidation is the most effective approach to maximize shareholder value given the circumstances. This move follows a strategic review initiated after challenges with its main drug candidate.
If You Invested $1,000 in Third Harmonic Bio Inc (THRD)
This article analyzes hypothetical investment returns for Third Harmonic Bio Inc (THRD) over different periods, demonstrating significant losses for investors over five and ten years, while showing a positive return over one year despite the company's eventual dissolution. It details the company's focus on developing THB335 for inflammatory diseases, its clinical trials, and the strategic decision to liquidate and dissolve, leading to the delisting of its stock from Nasdaq. The company's remaining activities revolve around winding down operations and distributing assets to shareholders.
THRD - Third Harmonic Bio Inc Latest Stock News & Market Updates
This page provides news and updates for Third Harmonic Bio (THRD), a clinical-stage biopharmaceutical company focusing on inflammatory diseases. The company initially focused on developing KIT inhibitors like THB335 and THB001, but later announced a strategic shift towards liquidation and dissolution. The news archive covers clinical data, financial reporting, and the eventual decision to wind down operations.
Third Harmonic Bio Form 4: RSUs Settled and Shares Cancelled in Dissolution
A recent Form 4 filing for Third Harmonic Bio, Inc. (THRD) revealed that Christopher M. Murphy, the Chief Financial & Business Officer, had 47,500 Restricted Stock Units (RSUs) settled and cancelled on August 11, 2025. This transaction involved a liquidation distribution of $5.35 per share, reflecting the company's dissolution. Following this, Mr. Murphy beneficially owns 0 common shares, signaling the termination of equity stakes for shareholders as part of the dissolution proceedings.
Third Harmonic Bio Inc. (THRD) Stock Price | Live Quotes & Charts | NASDAQ
This page provides live stock quotes and charts for Third Harmonic Bio Inc. (THRD) on NASDAQ. It shows the current stock price and highlights that there are no analyst ratings or earnings information currently available for the company. The page also promotes a virtual trading conference and free trade alerts.
Third Harmonic Bio Inc. (THRD) Stock Price | Live Quotes & Charts | NASDAQ
This page provides live stock quotes and charts for Third Harmonic Bio Inc. (THRD) on NASDAQ. It shows the current stock price and highlights that there are no analyst ratings or earnings information currently available for the company. The page also promotes various trading tools, educational content, and offers free trade alerts.
Third Harmonic Bio Plans Nasdaq Delisting by July 31
Third Harmonic Bio, Inc. (THRD) announced its intention to voluntarily delist its common stock from Nasdaq and deregister under the Securities Exchange Act as part of a planned dissolution. The company expects to cease trading on July 31, 2025, and has approved a liquidation distribution of $5.35 per share, with the first distribution anticipated in August 2025. Key executives will depart as part of this process, underscoring operational challenges identified by TipRanks' AI Analyst, Spark.
Third Harmonic Bio to delist from Nasdaq and announces liquidation distribution
Third Harmonic Bio Inc. (NASDAQ: THRD) has announced its intention to delist from Nasdaq and deregister its common stock as part of a liquidation and dissolution plan approved by stockholders. The company plans to file a Form 25 around July 31, 2025, with trading expected to suspend before then, and will subsequently distribute $5.35 per share to stockholders, with the first distribution anticipated in August 2025. Several executives will depart, and the company is also initiating a sale process for its clinical asset THB335.
AstraZeneca forms an AI deal in China; Third Harmonic advances liquidation plans
AstraZeneca has partnered with CSPC Pharmaceutical Group to use AI for discovering oral drugs for immunological and chronic conditions, with a potential deal value up to $5.3 billion. Meanwhile, Third Harmonic Bio is liquidating, planning to return $5.30 to $5.44 per share to stockholders and auctioning an experimental drug for chronic hives. Other news includes UCB's plan for a new biologics manufacturing plant in the U.S., Insmed raising $750 million after positive Phase 2 results, and UroGen Pharma receiving FDA approval for a bladder cancer drug despite an advisory panel's reservations.
Finance Watch: Insmed Cashes In On Positive Data With $750m Offering
Insmed capitalized on positive data by announcing a $750 million offering. The article highlights Insmed's potential to surpass established therapies with its PAH data and plans for a 2025 launch of brensocatib.
Third Harmonic Bio Shareholders Win Big: $5.35/Share Payout Approved as Drug Shows 85% Efficacy
Third Harmonic Bio (THRD) shareholders have approved the company's liquidation and dissolution plan, with an initial distribution of $5.30-$5.35 per share expected in Q3 2025, and total distributions estimated to reach $5.30-$5.44 per share. Concurrently, THRD announced positive Phase 1 clinical trial data for THB335, an oral wild-type KIT inhibitor, showing 85% serum tryptase reduction and an encouraging safety profile. The company is seeking FDA clearance for Phase 2 trials and has initiated a sale process for THB335 and its related intellectual property.
Here’s Why Third Harmonic Bio (THRD) Fell in Q1
Third Harmonic Bio (THRD) experienced a decline in Q1 after its primary drug, THB001, caused liver toxicity issues in trials and subsequent Phase 1 data for THB335 also disappointed investors. Despite a recent one-month return of 48.28%, the biopharmaceutical company's shares fell 55.90% over the past 52 weeks. 1 Main Capital highlighted THRD in its Q1 2025 investor letter but noted a stronger conviction in AI stocks for higher and quicker returns.
THRD Stock Price, News & Analysis
Third Harmonic Bio (THRD) was a clinical-stage biopharmaceutical company focused on developing small-molecule inhibitors of KIT for inflammatory diseases, with its lead candidate being THB335. The company initiated a Plan of Liquidation and Dissolution, which was overwhelmingly approved by stockholders, leading to the delisting of its common stock from Nasdaq and the termination of its SEC reporting obligations in mid-2025. As of August 1, 2025, THRD stock last traded at $5.38, having lost 56.8% over the prior 12 months, and the company's remaining activities are focused on asset liquidation and distribution to shareholders.
SF biotech company, once worth nearly $1 billion, plans to shut down
Third Harmonic Bio, a San Francisco biotech company once valued at nearly $1 billion, plans to shut down, liquidate its assets, and distribute remaining cash to stockholders. This decision follows a 50% staff reduction and a significant drop in its market capitalization. The company intends to sell off its hives drug prospect and expects a stockholder vote on the liquidation plan in June.
Third Harmonic's shutdown, Coherus and Xoma drug sales connected - Bizwomen
Amid a prolonged downturn in the biotech industry, several companies are making significant strategic moves. Third Harmonic Bio is shutting down and returning cash to shareholders, while Coherus BioSciences is selling an anemia drug to focus on cancer therapies, and Xoma Royalty Corp. has divested five drugs it acquired last year. These actions highlight a trend of biotech firms adjusting to a challenging funding landscape by divesting assets, returning value to shareholders, or realigning their strategic focus.
Third Harmonic's shutdown, Coherus and Xoma drug sales connected - Bizwomen
Amid a prolonged biotech downturn, several Bay Area drug companies are making strategic moves to adapt. Third Harmonic Bio will shut down and return funds to shareholders, Coherus BioSciences sold its biosimilar anemia drug to focus on oncology, and Xoma Royalty Corp. sold five drugs it acquired recently, highlighting a trend of asset divestment and restructuring in the industry.
Third Harmonic Bio to Return $255M to Shareholders in Major Cash Distribution
Third Harmonic Bio announced a Plan of Liquidation and Dissolution, subject to stockholder approval on June 5, 2025. The company plans an initial cash distribution of $246.6 million to $255.4 million, or $5.13 to $5.33 per share, in Q3 2025 by liquidating assets, including the THB335 program. Following approval, the company will delist from Nasdaq and resolve outstanding liabilities, with a total estimated distribution eventually reaching $5.13 to $5.42 per share.
Third Harmonic Bio: In Focus for Strategic Moves
Third Harmonic Bio (NASDAQ: THRD) saw its stock surge 39.42% after revealing promising Phase 1 data for its THB335 program and securing FDA designation, which boosted investor confidence. The company plans to initiate a Phase 2 study for THB335 in chronic spontaneous urticaria (CSU) by mid-2025 and is exploring strategic options like business combinations to enhance shareholder value, backed by a strong cash reserve of $285.1M despite a recent EPS loss.
Third Harmonic Bio Announces Plan of Liquidation and Dissolution
Third Harmonic Bio (Nasdaq: THRD) announced that its board of directors has approved a Plan of Liquidation and Dissolution, intending to seek stockholder approval on June 5, 2025. The plan involves liquidating the company, distributing remaining cash to stockholders, and selling assets including the THB335 program. An initial distribution of approximately $5.13 to $5.33 per share is expected in the third quarter of 2025.
Third Harmonic's $285M War Chest Powers Phase 2 CSU Drug Development Amid Strategic Shift
Third Harmonic Bio (THRD) reported strong financial results for Q4 and full year 2024, with $285.1 million in cash and cash equivalents, projected to fund operations through 2026. The company successfully completed Phase 1 trials for THB335, its oral KIT inhibitor for chronic spontaneous urticaria (CSU), and plans to initiate a Phase 2 study by mid-2025. Amidst this progress, THRD has undertaken a strategic restructuring, halting non-THB335 research and reducing its workforce by 50% to maximize shareholder value.
Third Harmonic Bio initiates process to identify opportunities to maximize value
Third Harmonic Bio (THRD) has initiated a process to explore strategic options, including a potential transaction or business combination, to maximize shareholder value. This decision comes as the company continues preparations for Phase 2 readiness of its THB335 program, following a significant workforce reduction and halting of non-THB335 research activities in February 2025. Despite these changes, the company reports a strong financial position, with estimated cash and cash equivalents of $262 million to $267 million by mid-2025.
Atlas unveils a new $450M fund targeted at biotechs 2 years after its last
Atlas Venture has announced a new $450 million fund, its fourteenth, dedicated to innovative biotechs, matching the size of its previous fund from March 2022. Since then, the firm has launched 16 new biotechs and seen significant exits including acquisitions by Eli Lilly, GSK, and Novartis, alongside several public listings. This new fund reinforces Atlas's focused venture creation strategy within the biotech sector, following other large investment announcements in the industry.
Third Harmonic Bio Inc (THRD) Stock Price, News & Analyst Forecast
Third Harmonic Bio Inc (THRD) stock is currently priced at $5.36, experiencing a slight decline over the past day and week. The biopharmaceutical company, founded in 2019, focuses on developing treatments for inflammatory diseases by targeting mast cells, with its lead candidate being THB335. The article also provides key financial metrics for THRD, information on how to purchase its stock, and frequently asked questions regarding its price and market capitalization.
Third Harmonic Bio Appoints Christopher Murphy as Chief Financial Officer
Third Harmonic Bio has announced the appointment of Christopher Murphy as its new Chief Financial Officer. Murphy brings extensive experience in business development, commercial operations, corporate strategy, and investment banking within the biopharmaceutical industry. In his new role, he will be responsible for leading the company's finance, corporate strategy, and business development functions.
Third Harmonic Bio Appoints Geoff McDonough, M.D., to its Board of Directors
Third Harmonic Bio (Nasdaq: THRD) announced the appointment of Geoff McDonough, M.D., to its Board of Directors. Dr. McDonough brings extensive operational leadership and clinical experience, which will be valuable as the company advances its lead product candidate, THB335, into clinical trials for chronic spontaneous urticaria. He previously served as President and CEO of Generation Bio Co. and Swedish Orphan Biovitrum AB (Sobi), and held senior roles at Genzyme Corporation.
Third Harmonic halts study of lead drug over safety risk
Third Harmonic Bio has halted development of its lead drug after two participants in an early clinical trial showed signs of liver toxicity. This setback caused the company's shares to drop by over 75%, despite its earlier success in 2022, including a $185 million IPO. The company plans to focus on developing new drug candidates targeting the same cellular regulator, KIT, and believes the toxicity is compound-specific rather than related to the target.
Safety Issue Trips Third Harmonic Months After IPO
Third Harmonic Bio announced the discontinuation of its Phase Ib trial for THB001, its lead asset aimed at treating chronic inducible urticaria, due to two patients developing asymptomatic liver transaminitis. Despite showing preliminary clinical activity, the decision caused the company's stock to drop by 75%. This setback highlights the risks associated with early-stage biotech investments, especially in a challenging economic climate for IPOs.
THRD - Third Harmonic Bio Inc Latest Stock News & Market Updates
This page provides news and analysis for Third Harmonic Bio (THRD), a biopharmaceutical company that focused on inflammatory diseases before deciding to liquidate. Recent updates detail the company's plan of liquidation and dissolution, including stockholder approval, expected distributions per share, and the initiation of a sale process for its lead asset, THB335. The news archive also covers earlier financial results and clinical trial progress for THB335.
Third Harmonic Bio Appoints Thomas M. Soloway to its Board of Directors
Third Harmonic Bio, Inc., a clinical-stage biopharmaceutical company, announced the appointment of Thomas M. Soloway to its Board of Directors. Soloway brings over 25 years of experience in the life sciences industry, holding senior roles in strategy, operations, corporate finance, and venture capital. His expertise will be valuable as the company scales and advances its lead product candidate, THB-001, for severe allergy and inflammation.
Atlas-backed Third Harmonic draws $155M, advances c-Kit inhibitor
Third Harmonic, backed by Atlas Venture, has secured $155 million to further develop its oral c-Kit inhibitor, THB001. The company aims to treat a variety of allergic and inflammatory conditions, starting with urticaria, due to the drug's selective targeting capabilities. Third Harmonic believes this molecule offers a pipeline-in-a-product opportunity for multiple disease areas.
Natalie Holles lands at freshly funded biotech startup focused initially on hives
Natalie Holles has been appointed CEO of Third Harmonic Bio, a biotech startup that has secured $105 million in funding. The company, initially focused on treating hives, marks Holles' return to a CEO role after her previous position with a late-stage gene therapy company. This move signifies a new chapter for Holles, leading a smaller company targeting a significant disease.
Startup targeting allergies launches with Novartis drug, $155M
Third Harmonic Bio has launched from stealth with an impressive $155 million in funding, focusing on developing treatments for allergies. The company's debut is notably associated with a Novartis drug, underscoring a significant entry into the life sciences sector. Natalie Holles is the CEO of Third Harmonic Bio.
